Publication | Open Access

Discovery of orally active indirubin-3′-oxime derivatives as potent type 1 FLT3 inhibitors for acute myeloid leukemia

Hematological MalignancyActive Indirubin-3′-oxime DerivativesOncologyMedicineAcute Myeloid LeukemiaPharmacotherapyAnti-cancer AgentPotent Type 1PharmacologyRadiation OncologyPharmaceutical ChemistryDrug Discovery